ImmunSkills: Pioneering Cellular Therapy for Cancer Treatment

Based at the BioArk Monthey technology site and supported by The Ark Foundation, ImmunSkills has been highlighted by Le Monde Économique through an in-depth interview with its CEO Adolfo Gonzalez.

The startup is revolutionizing cancer treatment through innovative cellular therapy techniques that promise more effective and accessible therapeutic approaches. ImmunSkills SA is at the forefront of modern medicine, focusing on developing novel cellular therapies to combat cancer, particularly solid tumors.

By genetically modifying immune cells, specifically Natural Killer (NK) cells, ImmunSkills enhances their ability to resist hostile tumor microenvironments and attack solid tumors more effectively. The company’s innovative approach involves using NK cells from healthy donors, which are then modified to target specific cancer types, offering a potentially more accessible and scalable treatment option.

Advancing Cellular Therapy Through Innovation

ImmunSkills’ approach goes beyond improving cancer treatments. The company is redefining the entire process of developing and delivering these innovative therapies.

Their advanced technological platform enables large-scale production of therapeutic cells, facilitating rapid and efficient access to treatments. What sets ImmunSkills apart is their close collaboration with clients, who develop the specific recognition domain for cancer detection. ImmunSkills then integrates this genetic sequence into their specialized immune cells, creating a tailored therapeutic solution.

Overcoming Challenges in Cancer Treatment

One of the key challenges in cancer treatment is the high cost and lengthy development time of personalized therapies. ImmunSkills addresses this by focusing on allogeneic cell therapies rather than individual personalization. By using cells from healthy donors, the company can produce cell therapies on a large scale, which can be stored and distributed quickly as needed. This allogeneic method represents a significant advancement in cellular therapy, potentially reducing treatment costs and increasing accessibility.

CEO Adolfo Gonzalez emphasizes the importance of Switzerland’s supportive ecosystem for biotech innovation, highlighting the country’s excellent infrastructure, highly skilled workforce, and favorable regulatory environment. He also notes the critical role of funding in advancing cellular therapy research and development, acknowledging the support received from various sources, including The Ark Foundation.

Read the full article (in French) 

Discover ImmunSkills

31 January 2025
Scroll to Top